Thermo Fisher Scientific Inc. $TMO Position Lifted by Pittenger & Anderson Inc.

Key Points

• Pittenger & Anderson Inc. increased its Thermo Fisher Scientific stake by 545.2% in the first quarter, ending with 7,742 shares valued at about $3.8 million.
• Thermo Fisher reported better-than-expected quarterly results, with EPS of $5.44 versus $5.25 estimated and revenue of $11.01 billion versus $10.86 billion expected; revenue rose 6.2% year over year.
• The company also declared a quarterly dividend of $0.47 per share and, despite some analysts trimming price targets, Wall Street still sees the stock as a Moderate Buy with a consensus target of $602.14.

Pittenger & Anderson Inc. grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 545.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,742 shares of the medical research company's stock after acquiring an additional 6,542 shares during the period. Pittenger & Anderson Inc.'s holdings in Thermo Fisher Scientific were worth $3,805,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. High Note Wealth LLC lifted its holdings in Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock worth $27,000 after buying an additional 29 shares during the last quarter. Swiss RE Ltd. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $28,000. Beacon Financial Strategies CORP acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at approximately $29,000. Olistico Wealth LLC acquired a new position in Thermo Fisher Scientific in the fourth quarter worth $29,000. Finally, Birchwood Financial Partners Inc. bought a new stake in Thermo Fisher Scientific during the fourth quarter valued at $29,000. Institutional investors own 89.23% of the company's stock.

Insider Buying and Selling

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the business's stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares of the company's stock, valued at $11,590,095.66. The trade was a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Up 0.4%

Shares of NYSE TMO traded up $2.01 during mid-day trading on Friday, reaching $526.72. The company had a trading volume of 1,233,008 shares, compared to its average volume of 1,993,707. The company has a market capitalization of $195.74 billion, a price-to-earnings ratio of 28.96, a PEG ratio of 2.33 and a beta of 0.87. Thermo Fisher Scientific Inc. has a 12-month low of $403.36 and a 12-month high of $643.99. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The stock has a fifty day moving average of $478.23 and a two-hundred day moving average of $516.44.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating analysts' consensus estimates of $5.25 by $0.19. The firm had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business's quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 24.84 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.4%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.34%.

Analyst Upgrades and Downgrades

TMO has been the topic of a number of recent research reports. Robert W. Baird reduced their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a research report on Friday, April 24th. Stifel Nicolaus dropped their price objective on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a "buy" rating on the stock in a research note on Friday, April 24th. Wells Fargo & Company decreased their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating for the company in a research note on Friday, May 8th. Piper Sandler assumed coverage on shares of Thermo Fisher Scientific in a report on Thursday, June 11th. They set a "neutral" rating and a $510.00 price target for the company. Finally, Wolfe Research started coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They set an "outperform" rating and a $535.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat.com, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and a consensus target price of $602.14.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.